EDNRA and pulmonary arterial hypertension: The development of endothelin receptor antagonists (ERAs) such as bosentan, a dual EDNRA and EDNRB receptor antagonist, or BQ123 targeting EDNRA, provided targeted treatments for pulmonary arterial hypertension and cancer22–26.